Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,239 total articles
CME Group is uniquely exposed to sustained volatility and higher rates that are lifting futures volumes and fees. With a $96B market cap, 4.2% dividend yield and strong free cash flow, CME looks like a reasonable mid-term long while macro volatility persists. This trade lays out a specific entry at $266.07, a stop at $255.00 and a 45-trading-day ta…
The Charles Schwab Corporation just printed an all-time high in free cash flow, giving the firm flexibility to buy back stock, support dividends, and invest in growth. With reasonable valuation metrics (EV/EBITDA ~8.7, P/E ~17.5) and technicals near the 50-day average, this is a tactical long for investors who want income-plus-growth exposure to th…
Pernod Ricard offers a durable earnings base, pricing power in premium spirits, and a balance sheet able to support buybacks and acquisitions. Valuation looks attractive relative to the company's franchise strength. We lay out an actionable long-term trade with entry, stop and target, plus catalysts and risks to watch.
Ameriprise combines sticky advisory revenues with a capital-light asset management arm and sizable free cash flow. Trading around $460 with a market cap near $41.3B, the stock is inexpensive on P/E (~10.6) and P/FCF (~5.96) metrics while delivering a rare ROE of ~62.7%. We present a long trade plan with an entry at $460, stop at $420 and a target a…
Zimmer Biomet is a steady cash generator in orthopedics with a market cap of roughly $17.1B, an FCF yield north of 6%, and room to rerate if procedure volumes and product adoption in high-growth niches (orthobiologics, foot & ankle, wound care) accelerate. This trade favors a controlled long with a 45-trading-day horizon: entry near $88.26, stop at…
IBM is not a breakout growth story, but it is a cash-generative, high-ROE technology services firm positioned to benefit from enterprises shifting AI to on-prem and hybrid cloud architectures. At roughly $252.5B market cap, IBM's earnings power, dividend yield and nascent quantum/AI catalysts make it a reasonable candidate for multiple expansion. T…
Marubeni (MARUY) looks set for a mid-term re-rating after investor-day takeaways: clearer capital-return discipline across trading-house peers, a material offtake and equity tie-up in low-carbon ammonia with Exxon (05/08/2025), and renewed institutional demand from Berkshire-linked allocations (04/23/2026). At a $52.6B market cap and a P/E of ~14, …
Recent ASCO data and multiple positive signals across Immatics' PRAME programs (anzu-cel/IMA203 and next-gen assets) argue that PRAME is becoming a platform rather than a single therapy. With a market cap of $1.27B, a $125M equity raise behind it, and a Phase 3 program on track for BLA submission in H1 2027, Immatics presents a high-reward long tra…
DNOW appears mispriced relative to balance-sheet strength and recurring free cash flow. The shares trade near 1.17x book and 0.73x sales, while the company generates positive free cash flow and carries modest leverage. Short-term headline risk and a negative EPS readout have pushed the stock below earlier levels; we see a mid-term opportunity to bu…
General Dynamics (GD) combines steady organic growth, strong free cash flow and a manageable balance sheet with direct exposure to rising naval and defense budgets. Trading at ~22x trailing earnings with an EV/EBITDA of 16.4 and free cash flow of roughly $6.2B, GD looks like a defensive-growth name you can own through geopolitical noise. This is a …
Red Cat (RCAT) is a high-volatility, high-upside drone play. Recent product launches (Hellcat on 06/15/2026), ramping maritime production and Pentagon programs are beginning to show up in orders and partner integrations. At the same time the stock trades with a $1.82B market cap, negative earnings and stretched multiples. This trade targets near-te…
Thales is well positioned to benefit from a multi-year increase in defense and secure communications spending. Buy into weakness with a clear entry at $80.00, a protective stop at $68.00 and a $100.00 target over a long-term (180 trading days) horizon. The setup balances asymmetric upside from large program awards and margin expansion against execu…
Cisco owns the enterprise networking stack that underpins large-scale AI deployments. Strong cash flow, low leverage, and a valuation that still lags direct AI infrastructure players make CSCO an actionable mid-term long. Entry $120.20, target $140.00, stop $112.00; horizon 45 trading days.
Ryanair's ultra-low-cost model, healthy balance-sheet footprint and recent market momentum make it the likeliest European carrier to recover first from the jet-fuel shock tied to the Middle East. This trade lays out a clear entry at $62.00, a stop at $55.00 and a target at $74.24 (the 52-week high), with a 180-trading-day horizon.
Plains All American (PAA) yields roughly 7% today, trades at modest multiples (P/FCF ~7.5, EV/EBITDA ~11.7) and generates meaningful free cash flow. With a pending NGL sale that simplifies the business and support for distributions, I recommend a long trade for income and capital appreciation over a 180 trading day horizon, entry $22.00, target $26…
Atlassian is staging a disciplined recovery after the post-SaaSpocalypse sell-off. Positive free cash flow, reasonable EV/sales and shrinking short interest combined with AI-driven demand for collaboration tools make a compelling mid-term trade. Entry at $92.00, stop at $81.00, target at $125.00 — mid term (45 trading days) plan that balances upsid…
Fluence (FLNC) is trading at a valuation that reflects execution risk, capital intensity and a volatile revenue ramp. Recent commercial wins with hyperscalers and a structurally expanding BESS market make a controlled long trade attractive. Enter at $24.00, stop $19.50, target $33.50 over a mid-term 45 trading day horizon; position size should refl…
AST SpaceMobile (ASTS) trades like a high-beta growth name but has quietly become a credible defense supplier and launch partner client, creating a practical pathway from speculative broadband dreams toward contract-backed revenue. This trade idea lays out a long entry at $87.60, a stop at $72.00 and a target of $125.00 over a long-term (180 tradin…
Lumen is transitioning from a legacy consumer-heavy footprint to an enterprise-focused provider of fiber and AI-optimized networking. Recent NaaS wins, a materially lower share price from last year's peak, and an improving cash profile create a trade that offers upside to $10.50 while limiting downside risk with a $7.25 stop. We lay out the thesis,…
Wintrust shares have run up near their 52-week highs while airborne short interest and elevated valuation leave the stock vulnerable to a catalyst that shifts sentiment toward downgrades. This trade idea lays out a tactical short with a clear entry, stop, and target over a mid-term (45 trading days) horizon.
AMD is trading near $547 after a dramatic rerating as agentic AI shifts demand toward inference-optimized CPUs and accelerators. Fundamentals show robust free cash flow ($8.57B) and a clean balance sheet (debt/equity ~0.05), but valuation is stretched (P/E ~168, price/sales ~22.3). This trade idea lays out a mid-term long: entry $547.27, stop $485.…
Trilogy Metals (TMQ) is a speculative copper play trading near $4.07 with a market cap around $716M. Recent U.S. government involvement and the company's Bornite/Arctic projects create a near-term narrative; this trade idea targets $6.50 on a 45-trading-day horizon with a $3.10 stop, but carries significant execution, permitting and financing risk.
LendingClub's evolution from a marketplace lender to a digital, deposit-taking bank is moving from strategy into results. With origination growth re-accelerating, net charge-offs declining and valuation sitting near 1.3x book and ~12x earnings, the stock offers asymmetric upside if execution continues. This trade idea lays out an entry, stop and ta…
Salesforce ($CRM) is positioning itself as the connective tissue between enterprise data and AI agents. The stock has pulled back to $165 after a 52-week peak near $277; the balance sheet and free cash flow support continued investment in Data 360, Agentforce, and recently acquired integration tooling. This trade idea targets $210 with a hard stop …
Sanofi looks attractively valued against a $106.6B market cap, a ~3.99% yield and improving specialty franchise momentum. Recent regulatory progress and signs of commercial durability in its specialty portfolio make a long trade with a clear entry, stop and target compelling over a 180 trading-day horizon.
